What types of diseases or cancers is Platinib suitable for?

Pralsetinib is a targeted drug that specifically targets RET gene fusions or mutations. Its indications are mainly concentrated in malignant tumors with clear RET gene changes. The main applicable disease is RET fusion-positive non-small cell lung cancer (NSCLC). Especially for patients whose traditional EGFR, ALK, ROS1 and other driver gene tests are negative but whose RET gene fusion positivity is confirmed by NGS testing, Platinib provides a new option for personalized targeted therapy.

Such patients usually have a poor response to traditional chemotherapy and immunotherapy, so the use ofRET inhibitors can significantly improve efficacy and prolong progression-free survival. In addition to lung cancer, platinib is also approved for the treatment of advanced or metastatic RET-mutant papillary thyroid cancer (PTC) and medullary thyroid cancer (MTC), especially in patients who have failed or are intolerant to other multi-target tyrosine kinase inhibitors (such as vandetanib, cabozantinib). In addition, platinib has also shown potential application value in other RET fusion-positive solid tumors, such as pancreatic cancer, cholangiocarcinoma, colorectal cancer, etc., but more clinical research data are needed to support its widespread promotion.

It needs to be emphasized that the prerequisite for using Platinib is clear RET gene test results. Current international guidelines recommend accurate identification of RET fusions or mutations through NGS platforms such as RNA sequencing or DNA sequencing, which is also a key basis for the success of targeted therapy. Since the incidence of RET gene fusion is low in the overall population, platinib belongs to the category of precision medicine, and its efficacy depends on the matching of individual molecular characteristics, so it is not suitable for all cancer patients.

In clinical use, it is recommended to cooperate with professional oncologists for individual assessment and make treatment decisions based on genetic testing results, patient course and tolerance. With the continuous development of targeted drug research and development, platinib is gradually expanding its scope of application and becoming an important part of the treatment field for RET abnormal tumors.

Reference: https://gavreto.com/